According to Takeda Pharmaceuticals, the average time taken to diagnose a rare disease without technology is 7.6 years, and that comes after countless tests and physician visits.
Companies in the life sciences industry must ensure they have the systems and tools to be able to consistently provide a product that is safe and effective and that is delivered in a timely
Before getting lost in the vast options a decentralised clinical trial (DCT) setup provides, sponsors considering a DCT model need to keep in mind that it is not a one-size-fits-all approac
This year, the predicted flurry of merger and acquisition (M&A) activity might not have materialised. However, as we near the end of the year, there were some big moves.
Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho